Table 1.
The characteristics of the included studies
| Author | Location | Treatment stage | Sample size | Age# | Trial Abbr. | Register No. | HER2 detection | Intervention¶ | Control¶ | Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|
| K. Shitara 2020[20] | Japan/Korea | Third-Line | 187 | 65 (28-82) | DESTINY-Gastric01 | NCT03329690 | IHC 3+ or IHC 2+/ISH+ | TrastuzumabDeruxtecan (TraD) | Irintecan/Paclitaxel (Chemo) | 5 years |
| Akitaka Makiyama 2020[21] | Japan | Second-line | 91 | 67 (33-89) | WJOG7112G/T-ACT | UMIN000009297 | IHC 3+ or IHC 2+/ISH+ | Trastuzumab; Ppaclitaxel (TraChemo) | Paclitaxel (Chemo) | 54 months |
| JosepTabernero 2018[22] | Multicenter | First-line | 780 | 61 (54-69)§ | JACOB | NCT01774786 | IHC 3+or IHC 2+/ISH+ | Pertuzumab; Trastuzumab; Cisplatin; Capecitabine/5-fluorouracil (PerTraChemo) | Placebo; Trastuzumab; Cisplatin; Capecitabine/5-fluorouracil (TraChemo) | 42 months |
| Yongli Xin 2017[23] | China | First-line | 30 | 45 (18-68) | NA | NA | IHC 1+to 3+ | Lapatinib; Paclitaxel (LapChemo) | Paclitaxel (Chemo) | 3 years |
| PC Thuss-Patience 2017[24] | Multicenter | Second-line | 345 | 62 (19-80) | GATSBY | NCT01641939 | IHC 3+or IHC 2+/ISH+ | TrastuzumabEmtansine (TraE) | Docetaxel/Paclitaxel (Chemo) | 33 months |
| MA. Shah 2017[25] | Multicenter | First-line | 248 | 62 (26-83) | HELOISE | NCT01450696 | IHC 3+or IHC 2+/ISH+ | High-dose Trastuzumab; cisplatin; capecitabine (HTraChemo) | Standard of Care Trastuzumab; Cisplatin; Capecitabine (TraChemo) | 32 months |
| PETRARCA-AIO 2017[26] | Multicenter | First-line | 81 | 60 (NA) | PETRARCA-AIO | NCT02581462 | IHC 2+/3+and ISH+ | Trastuzumab; Pertuzumab; Docetaxel; Oxaliplatin; Leucovorin; 5- fluoruracil (PerTraChemo) | Docetaxel; Oxaliplatin; Leucovorin; 5-fluoruracil (Chemo) | 2 years |
| JR. Hecht 2015[27] | Multicenter | First-line | 545 | 61 (19-86) | TRIO-013/LOGiC | NCT00680901 | IHC 3+or ISH+ | Lapatinib; Capecitabine; Oxaliplatin (LapChemo) | Capecitabine; Oxaliplatin (Chemo) | 48 months |
| CS. Denlinger 2017[28] | US | Second-line | 84 | 63 (31-81) | NA | NCT01774851 | HER2 Gene Amplification | MM-111; Trastuzumab; Paclitaxel (MM111TraChemo) | Trastuzumab; Paclitaxel (TraChemo) | 56 weeks |
| MH. Moehler 2016[29] | Multicenter | First-line | 28 | NA | EORTC 40071 | NCT01123473 | IHC 2/3+or EGFR1 ISH+ | Lapatinib; Epirubicin; Cisplatin; 5-fluoruracil/Capecitabine (LapChemo) | Placebo; Epirubicin; Cisplatin; 5-fluoruracil/Capecitabine (Chemo) | 2 years |
| S. Lorenzen 2015[30] | Multicenter | Second-Line | 37 | 56 (44-75) | AIO | NCT01145404 | IHC3+or 2+ | Lapatinib; Capecitabine (LapChemo) | Lapatinib (Lap) | 18 months |
| T. Satoh 2014[31] | Japan | Second-line | 261 | 61 (22-80) | TyTAN | NCT00486954 | ISH+ | Lapatinib; Paclitaxel (LapChemo) | Paclitaxel (Chemo) | 45 months |
| YJ. Bang 2010[32] | Multicenter | First-line | 594 | 59±11 | ToGA | NCT01041404 | IHC 3+or ISH+ | Trastuzumab; Cisplatin; Capecitabine/5-fluoruracil (TraChemo) | Cisplatin; Capecitabine /5-fluoruracil (Chemo) | 36 months |
EGFR1: Epidermal growth factor receptor 1; IHC: immunohistochemistry; ISH: in situ hybridization; NA: Not available. #Age was present as Median (minimum-maximum) or Mean±Standard Deviation. §Median (interquartile range). ¶Targeted agents and cytotoxic drug used in treatment, and the abbreviations list in brackets for meta-analysis